The effects of mutant Ras proteins on the cell signalome

Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a

Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997) · Cell · doi:10.1016/s0092-8674(00)81902-9 · Cited by 5,178 · see citing works

Anorexigenic and Orexigenic Hormone Modulation of Mammalian Target of Rapamycin Complex 1 Activity and the Regulation of Hypothalamic Agouti-Related Protein mRNA Expression

Watterson, K. R., Bestow, D., Gallagher, J. R., Hamilton, D. L., Ashford, F. B., Meakin, P. J., & Ashford, M. L. J. (2012) · Neurosignals · doi:10.1159/000334144 · Cited by 3,395 · see citing works

Cancer stem cells revisited

Batlle, E., & Clevers, H. (2017) · Nature Medicine · doi:10.1038/nm.4409 · Cited by 2,769 · see citing works

Correction: Corrigendum: The Serum Profile of Hypercytokinemia Factors Identified in H7N9-Infected Patients can Predict Fatal Outcomes

Guo, J., Huang, F., Liu, J., Chen, Y., Wang, W., Cao, B., Zou, Z., Liu, S., Pan, J., Bao, C., et al. (2016) · Scientific Reports · doi:10.1038/srep21230 · Cited by 2,148 · see citing works

The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation

Mendoza, M. C., Er, E. E., & Blenis, J. (2011) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2011.03.006 · Cited by 1,817 · see citing works

ERK/MAPK signalling pathway and tumorigenesis (Review)

Guo, Y., Pan, W., Liu, S., Shen, Z., Xu, Y., & Hu, L. (2020) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2020.8454 · Cited by 1,475 · see citing works

Intrinsic tumour suppression

Lowe, S. W., Cepero, E., & Evan, G. I. (2004) · Nature · doi:10.1038/nature03098 · Cited by 1,309 · see citing works

PI3K-Akt pathway: Its functions and alterations in human cancer

Osaki, M., Oshimura, M., & Ito, H. (2004) · APOPTOSIS · doi:10.1023/b:appt.0000045801.15585.dd · Cited by 1,266 · see citing works

RAS Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors

Su, F., Virós, A., Milagre, C. S., Trunzer, K., Bollag, G. E., Spleiss, O., Reis-Filho, J. S., Kong, X., Koya, R. C., Flaherty, K. T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1105358 · Cited by 1,038 · see citing works

Ras in Cancer and Developmental Diseases

Fernández‐Medarde, A., & Santos, E. (2011) · Genes & Cancer · doi:10.1177/1947601911411084 · Cited by 959 · see citing works

Biochemical and Structural Analysis of Common Cancer-Associated KRAS Mutations

Hunter, J. C., Manandhar, A., Carrasco, M. A., Gurbani, D., Gondi, S., & Westover, K. D. (2015) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-15-0203 · Cited by 786 · see citing works

A complex interplay between Akt, TSC2 and the two mTOR complexes

Huang, J., & Manning, B. D. (2009) · Biochemical Society Transactions · doi:10.1042/bst0370217 · Cited by 724 · see citing works

Ras signalling and apoptosis

Downward, J. (1998) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(98)80061-0 · Cited by 562 · see citing works

Mammalian Phospholipase C

Kadamur, G., & Ross, E. M. (2013) · Annual Review of Physiology · doi:10.1146/annurev-physiol-030212-183750 · Cited by 529 · see citing works

Ras Isoforms Vary in Their Ability to Activate Raf-1 and Phosphoinositide 3-Kinase

Yan, J., Roy, S., Apolloni, A., Lane, A., & Hancock, J. F. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.37.24052 · Cited by 477 · see citing works

PKC Regulates a Farnesyl-Electrostatic Switch on K-Ras that Promotes its Association with Bcl-Xl on Mitochondria and Induces Apoptosis

Bivona, T. G., Quatela, S. E., Bodemann, B. O., Ahearn, I. M., Soskis, M. J., Mor, A., Miura, J., Wiener, H. H., Wright, L. P., Saba, S. G., et al. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.01.012 · Cited by 467 · see citing works

Fibroblast immortality is a prerequisite for transformation by EJ c-Ha-ras oncogene

Newbold, R. F., & Overell, R. W. (1983) · Nature · doi:10.1038/304648a0 · Cited by 436 · see citing works

Many roads lead to oncogene-induced senescence

Courtois-Cox, S., Jones, S. L., & Cichowski, K. (2008) · Oncogene · doi:10.1038/sj.onc.1210950 · Cited by 397 · see citing works

Combinations of BRAF, MEK, and PI3K/mTOR Inhibitors Overcome Acquired Resistance to the BRAF Inhibitor GSK2118436 Dabrafenib, Mediated by NRAS or MEK Mutations

Greger, J., Eastman, S. D., Zhang, V., Bleam, M. R., Hughes, A. M., Smitheman, K. N., Dickerson, S. H., Laquerre, S. G., Liu, L., & Gilmer, T. M. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0989 · Cited by 366 · see citing works

Phospholipase Cϵ: a novel Ras effector

Kelley, G. G., Reks, S. E., Ondrako, J. M., & Smrcka, A. V. (2001) · The EMBO Journal · doi:10.1093/emboj/20.4.743 · Cited by 361 · see citing works

Oncogenic Roles of the PI3K/AKT/mTOR axis

Aoki, M., & Fujishita, T. (2017) · Current topics in microbiology and immunology · doi:10.1007/82_2017_6 · Cited by 355 · see citing works

Tiam1 mediates Ras activation of Rac by a PI(3)K-independent mechanism

Lambert, J. M., Lambert, Q. T., Reuther, G. W., Malliri, A., Siderovski, D. P., Sondek, J., Collard, J. G., & Der, C. J. (2002) · Nature Cell Biology · doi:10.1038/ncb833 · Cited by 326 · see citing works

A restricted spectrum of NRAS mutations causes Noonan syndrome

Cirstea, I. C., Kutsche, K., Dvorský, R., Gremer, L., Carta, C., Horn, D., Roberts, A. E., Lepri, F. R., Merbitz-Zahradnik, T., König, R., et al. (2009) · Nature Genetics · doi:10.1038/ng.497 · Cited by 315 · see citing works

Wildtype Kras2 can inhibit lung carcinogenesis in mice

Zhang, Z., Wang, Y., Vikis, H. G., Johnson, L., Liu, G., Li, J., Anderson, M. W., Sills, R. C., Hong, H. L. T., Devereux, T. R., et al. (2001) · Nature Genetics · doi:10.1038/ng721 · Cited by 295 · see citing works

Genomic and Biological Characterization of Exon 4 KRAS Mutations in Human Cancer

Janakiraman, M., Vakiani, E., Zeng, Z., Pratilas, C. A., Taylor, B. S., Chitale, D., Halilovic, E., Wilson, M., Huberman, K., Ricarte Filho, J. C., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0192 · Cited by 290 · see citing works

Protein kinase C (PKC) isoforms in cancer, tumor promotion and tumor suppression

Isakov, N. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.04.012 · Cited by 272 · see citing works

NMR-based functional profiling of RASopathies and oncogenic RAS mutations

Smith, M. J., Neel, B. G., & Ikura, M. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1218173110 · Cited by 257 · see citing works

NRAS mutation causes a human autoimmune lymphoproliferative syndrome

Oliveira, J. B., Bidère, N., Niemela, J. E., Zheng, L., Sakai, K., Nix, C. P., Danner, R. L., Barb, J. J., Munson, P. J., Puck, J. M., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0702975104 · Cited by 255 · see citing works

A Comparative Analysis of Individual RAS Mutations in Cancer Biology

Muñoz-Maldonado, C., Zimmer, Y., & Medová, M. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01088 · Cited by 250 · see citing works

Allosteric modulation of Ras positions Q61 for a direct role in catalysis

Buhrman, G., Holzapfel, G. A., Fetics, S., & Mattos, C. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0912226107 · Cited by 246 · see citing works

Signal Transduction Pathways in Breast Cancer: The Important Role of PI3K/Akt/mTOR

Ortega, M. A., Fraile‐Μartinez, O., Asúnsolo, Á., Buján, J., García‐Honduvilla, N., & Coca, S. (2020) · Journal of Oncology · doi:10.1155/2020/9258396 · Cited by 244 · see citing works

Many faces of Ras activation

Buday, L., & Downward, J. (2008) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2008.05.001 · Cited by 231 · see citing works

The Role of RASSF1A Methylation in Cancer

Hesson, L. B., Cooper, W. N., & Latif, F. (2007) · Disease Markers · doi:10.1155/2007/291538 · Cited by 219 · see citing works

PI3K/Akt-mediated regulation of p53 in cancer

Abraham, A., & O’Neill, E. (2014) · Biochemical Society Transactions · doi:10.1042/bst20140070 · Cited by 219 · see citing works

The Structural Basis of Oncogenic Mutations G12, G13 and Q61 in Small GTPase K-Ras4B

Lu, S., Jang, H., Nussinov, R., & Zhang, J. (2016) · Scientific Reports · doi:10.1038/srep21949 · Cited by 219 · see citing works

Mutation-Specific RAS Oncogenicity Explains NRAS Codon 61 Selection in Melanoma

Burd, C. E., Liu, W., Huynh, M. V., Waqas, M. A., Gillahan, J. E., Clark, K. S., Fu, K., Martin, B. L., Jeck, W. R., Souroullas, G. P., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0729 · Cited by 214 · see citing works

Extracellular-Regulated Kinases: Signaling From Ras to ERK Substrates to Control Biological Outcomes

Eblen, S. T. (2018) · Advances in cancer research · doi:10.1016/bs.acr.2018.02.004 · Cited by 212 · see citing works

Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers

Ebi, H., Corcoran, R. B., Singh, A., Chen, Z., Song, Y., Lifshits, E., Ryan, D. P., Meyerhardt, J. A., Benes, C., Settleman, J., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci57909 · Cited by 210 · see citing works

Crucial Role of Phospholipase Cε in Chemical Carcinogen-Induced Skin Tumor Development

Bai, Y., Edamatsu, H., Maeda, S., Saito, H., 昇, 鈴., Satoh, T., & Kataoka, T. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-3143 · Cited by 204 · see citing works

The Phospholipase C Isozymes and Their Regulation

Gresset, A., Sondek, J., & Harden, T. K. (2012) · Subcellular Biochemistry · doi:10.1007/978-94-007-3012-0_3 · Cited by 196 · see citing works

Targeting oncogenic Raf protein-serine/threonine kinases in human cancers

Roskoski, R. J. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.08.013 · Cited by 194 · see citing works

Ras Stabilization Through Aberrant Activation of Wnt/β-Catenin Signaling Promotes Intestinal Tumorigenesis

Jeong, W.-J., Yoon, J., Park, J., Lee, S.-H., Lee, S., Kaduwal, S., Kim, H., Yoon, J., & Choi, K. (2012) · Science Signaling · doi:10.1126/scisignal.2002242 · Cited by 189 · see citing works

Role of Oncogenic K-Ras in Cancer Stem Cell Activation by Aberrant Wnt/β-Catenin Signaling

Moon, B.-S., Jeong, W.-J., Park, J., Kim, T. I., Min, D. S., & Choi, K. (2014) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djt373 · Cited by 185 · see citing works

RAS-mediated oncogenic signaling pathways in human malignancies

Khan, A. Q., Kuttikrishnan, S., Siveen, K. S., Prabhu, K. S., Shanmugakonar, M., Al‐Naemi, H. A., Haris, M., Dermime, S., & Shahab Uddin, M. S. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.03.001 · Cited by 179 · see citing works

Sos-mediated cross-activation of wild-type Ras by oncogenic Ras is essential for tumorigenesis

Jeng, H., Taylor, L. J., & Bar‐Sagi, D. (2012) · Nature Communications · doi:10.1038/ncomms2173 · Cited by 176 · see citing works

Activating K-Ras mutations outwith ‘hotspot’ codons in sporadic colorectal tumours – implications for personalised cancer medicine

Smith, G. C., Bounds, R., Wolf, H., Steele, R. J., CAREY, F. A., & Wolf, C. R. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605534 · Cited by 176 · see citing works

Differential Activation of the Rac Pathway by Ha-Ras and K-Ras

Walsh, A. B., & Bar‐Sagi, D. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m010573200 · Cited by 173 · see citing works

Germline KRAS mutations cause aberrant biochemical and physical properties leading to developmental disorders

Gremer, L., Merbitz-Zahradnik, T., Dvorsky, R., Cirstea, I. C., Kratz, C. P., Zenker, M., Wittinghofer, A., & Ahmadian, M. R. (2011) · Human Mutation · doi:10.1002/humu.21377 · Cited by 158 · see citing works

Coordinate Direct Input of Both KRAS and IGF1 Receptor to Activation of PI3 kinase in <i>KRAS</i> -Mutant Lung Cancer

Molina-Arcas, M., Hancock, D. C., Sheridan, C., Kumar, M. S., & Downward, J. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0446 · Cited by 157 · see citing works

Somatic Mutations in H-RAS in Sporadic Pheochromocytoma and Paraganglioma Identified by Exome Sequencing

Crona, J., Verdugo, A. D., Maharjan, R., Stalberg, P. L. H., Granberg, D. O., Hellman, P., & Björklund, P. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-4257 · Cited by 146 · see citing works

Recurrent hotspot mutations in HRAS Q61 and PI3K-AKT pathway genes as drivers of breast adenomyoepitheliomas

Geyer, F. C., Li, A., Papanastasiou, A. D., Smith, A. E., Selenica, P., Burke, K. A., Edelweiss, M., Wen, H., Piscuoglio, S., Schultheis, A. M., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04128-5 · Cited by 140 · see citing works

p21-Activated Kinase 1 Is Required for Efficient Tumor Formation and Progression in a Ras-Mediated Skin Cancer Model

Chow, H. Y., Jubb, A. M., Koch, J. N., Jaffer, Z. M., Степанова, Д. С., Campbell, D. A., Durón, S. G., O’Farrell, M., Cai, K. Q., Klein–Szanto, A. J., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-2246 · Cited by 139 · see citing works

Mutant K-Ras Activation of the Proapoptotic MST2 Pathway Is Antagonized by Wild-Type K-Ras

Matallanas, D., Romano, D., Al‐Mulla, F., O’Neill, E. E., Al-Ali, W., Crespo, P., Doyle, B. J., Nixon, C., Sansom, O. J., Drosten, M., et al. (2011) · Molecular Cell · doi:10.1016/j.molcel.2011.10.016 · Cited by 133 · see citing works

Comparative analysis of KRAS codon 12, 13, 18, 61 and 117 mutations using human MCF10A isogenic cell lines

Stolze, B., Reinhart, S., Bullinger, L., Fröhling, S., & Scholl, C. (2015) · Scientific Reports · doi:10.1038/srep08535 · Cited by 132 · see citing works

High-throughput sequencing screen reveals novel, transforming RAS mutations in myeloid leukemia patients

Tyner, J. W., Erickson, H., Deininger, M. W., Willis, S. G., Eide, C. A., Levine, R. L., Heinrich, M. C., Gattermann, N., Gilliland, D. G., Druker, B. J., et al. (2008) · Blood · doi:10.1182/blood-2008-04-152157 · Cited by 131 · see citing works

Wilms tumor 1 (WT1) regulates KRAS-driven oncogenesis and senescence in mouse and human models

Vicent, S., Ron, C., Sayles, L. C., Lin, C., Walker, R. G., Gillespie, A. K., Subramanian, A., Hinkle, G., Yang, X., Saif, S., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci44165 · Cited by 131 · see citing works

Pan-Cancer Analysis Reveals Disrupted Circadian Clock Associates With T Cell Exhaustion

Wu, Y. C., Tao, B., Zhang, T., Fan, Y., & Mao, R. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02451 · Cited by 126 · see citing works

Regulation and physiological functions of mammalian phospholipase C

Nakamura, Y., & Fukami, K. (2017) · Journal of Biochemistry · doi:10.1093/jb/mvw094 · Cited by 122 · see citing works

Oncogenic Ras Isoforms Signaling Specificity at the Membrane

Nussinov, R., Tsai, C., & Jang, H. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-2727 · Cited by 122 · see citing works

Phase I, Open-Label, Dose-Escalation/Dose-Expansion Study of Lifirafenib (BGB-283), an RAF Family Kinase Inhibitor, in Patients With Solid Tumors

Desai, J., Gan, H. K., Barrow, C., Jameson, M. B., Atkinson, V. G., Haydon, A. M., Millward, M., Begbie, S. D., Brown, M. P., Markman, B., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02654 · Cited by 116 · see citing works

Modulation of EZH2 Expression by MEK-ERK or PI3K-AKT Signaling in Lung Cancer Is Dictated by Different KRAS Oncogene Mutations

Riquelme, E. M., Behrens, C., Lin, H. Y., Simon, G. R., Papadimitrakopoulou, V. A., Izzo, J. G., Moran, C. A., Kalhor, N., Lee, J. J., Minna, J. D., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-1141 · Cited by 113 · see citing works

Mechanisms of acquired resistance to ERK1/2 pathway inhibitors

Little, A. S., Smith, P. D., & Cook, S. J. (2012) · Oncogene · doi:10.1038/onc.2012.160 · Cited by 112 · see citing works

Ras signaling through RASSF proteins

Donninger, H., Schmidt, M., Mezzanotte-Sharpe, J., Barnoud, T., & Clark, G. J. (2016) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2016.06.007 · Cited by 110 · see citing works

The Contributions of Prostate Cancer Stem Cells in Prostate Cancer Initiation and Metastasis

Mei, W., Lin, X., Kapoor, A., Gu, Y. J., Zhao, K., & Tang, D. (2019) · Cancers · doi:10.3390/cancers11040434 · Cited by 109 · see citing works

Downregulation of the Ras activation pathway by MAP kinase phosphorylation of Sos.

Buday, L., Ph, W., & Downward, J. (1995) · PubMed · Cited by 106 · see citing works

miR-200c inhibits breast cancer proliferation by targeting KRAS

Song, C., Liu, L., Pei, X., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5198 · Cited by 100 · see citing works

Knockdown of PAK4 or PAK1 Inhibits the Proliferation of Mutant KRAS Colon Cancer Cells Independently of RAF/MEK/ERK and PI3K/AKT Signaling

Tabusa, H., Brooks, T., & Massey, A. J. (2012) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-12-0466 · Cited by 97 · see citing works

Molecular signaling in multiple myeloma: association of RAS/RAF mutations and MEK/ERK pathway activation

Xu, J., Pfarr, N., Endris, V, Mai, E. K., Md Hanafiah, N. H., Lehners, N., Penzel, R., Weichert, W., Ho, A. D., Schirmacher, P., et al. (2017) · Oncogenesis · doi:10.1038/oncsis.2017.36 · Cited by 89 · see citing works

Activation and Involvement of Ral GTPases in Colorectal Cancer

Martin, T. D., Samuel, J. C., Routh, E. D., Der, C. J., & Yeh, J. J. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-1517 · Cited by 88 · see citing works

The relative contributions of the p53 and pRb pathways in oncogene-induced melanocyte senescence

Haferkamp, S., Tran, S. L., Becker, T. M., Scurr, L. L., Kefford, R. F., & Rizos, H. (2009) · Aging · doi:10.18632/aging.100051 · Cited by 77 · see citing works

The RalB Small GTPase Mediates Formation of Invadopodia through a GTPase-Activating Protein-Independent Function of the RalBP1/RLIP76 Effector

Neel, N. F., Rossman, K. L., Martin, T. D., Hayes, T. K., Yeh, J. J., & Der, C. J. (2012) · Molecular and Cellular Biology · doi:10.1128/mcb.06291-11 · Cited by 71 · see citing works

PI3K: A Crucial Piece in the RAS Signaling PuzzlePreprint

Krygowska, A. A., & Castellano, E. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a031450 · Cited by 71 · see citing works

A functional switch from lung cancer resistance to susceptibility at the Pas1 locus in Kras2LA2 mice

To, M. D., Pérez‐Losada, J., Mao, J., Hsu, J., Jacks, T., & Balmain, A. (2006) · Nature Genetics · doi:10.1038/ng1836 · Cited by 69 · see citing works

Targeting the K-Ras - JNK axis eliminates cancer stem-like cells and prevents pancreatic tumor formation

Okada, M., Shibuya, K., Satō, A., Seino, S., Suzuki, S., Seino, M., & Kitanaka, C. (2014) · Oncotarget · doi:10.18632/oncotarget.2087 · Cited by 68 · see citing works

The structural basis for Ras activation of PI3Kα lipid kinase

Zhang, M., Jang, H., & Nussinov, R. (2019) · Physical Chemistry Chemical Physics · doi:10.1039/c9cp00101h · Cited by 67 · see citing works

ROS/KRAS/AMPK Signaling Contributes to Gemcitabine-Induced Stem-like Cell Properties in Pancreatic Cancer

Zhao, H., Wu, S., Li, H., Duan, Q., Zhang, Z., Shen, Q., Wang, C., & Yin, T. (2019) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2019.07.005 · Cited by 66 · see citing works

PAK Is Essential for RAS-Induced Upregulation of Cyclin D1 During the G1 to S Transition

Nheu, T. V., He, H. Z., Hirokawa, Y., et al. (2004) · Cell Cycle · doi:10.4161/cc.3.1.593 · Cited by 65 · see citing works

Structural insight into the rearrangement of the switch I region in GTP-bound G12A K-Ras

Xu, S., Long, B. N., Boris, G. H., Chen, A., Ni, S., & Kennedy, M. A. (2017) · Acta Crystallographica Section D Structural Biology · doi:10.1107/s2059798317015418 · Cited by 62 · see citing works

Interaction of the Wnt/β-catenin and RAS-ERK pathways involving co-stabilization of both β-catenin and RAS plays important roles in the colorectal tumorigenesis

Lee, S.-K., Hwang, J.-H., & Choi, K.-Y. (2018) · Advances in Biological Regulation · doi:10.1016/j.jbior.2018.01.001 · Cited by 61 · see citing works

The clinical relevance of KRAS gene mutation in non-small-cell lung cancer

Tı́már, J. (2014) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000051 · Cited by 59 · see citing works

NORE1A is a Ras senescence effector that controls the apoptotic/senescent balance of p53 via HIPK2

Donninger, H., Calvisi, D. F., Barnoud, T., Clark, J., Schmidt, M., Vos, M. D., & Clark, G. J. (2015) · The Journal of Cell Biology · doi:10.1083/jcb.201408087 · Cited by 55 · see citing works

Mutant Kras-induced upregulation of CD24 enhances prostate cancer stemness and bone metastasis

Weng, C., Ding, P.-Y., Liu, Y.-H., Hawse, J. R., Subramaniam, M., Wu, C.-C., Lin, Y.-C., Chen, C.-Y., Hung, W.-C., & Cheng, K. (2018) · Oncogene · doi:10.1038/s41388-018-0575-7 · Cited by 53 · see citing works

Tumor suppressor role of phospholipase Cε in Ras-triggered cancers

Martins, M., McCarthy, A., Baxendale, R. W., Guichard, S., Magno, L., Kessaris, N., El-Bahrawy, M. A., Yu, P., & Katan, M. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1311500111 · Cited by 51 · see citing works

Phospholipase C isozymes as effectors of Ras superfamily GTPases

Harden, T. K., Hicks, S. N., & Sondek, J. (2008) · Journal of Lipid Research · doi:10.1194/jlr.r800045-jlr200 · Cited by 50 · see citing works

Does Ras Activate Raf and PI3K Allosterically?

Nussinov, R., Tsai, C., & Jang, H. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01231 · Cited by 50 · see citing works

Durable Disease Control with MEK Inhibition in a Patient with NRAS-mutated Atypical Chronic Myeloid Leukemia

Khanna, V., Pierce, S. T., Dao, K.-H. T., et al. (2015) · Cureus · doi:10.7759/cureus.414 · Cited by 46 · see citing works

A mutant KRAS‐induced factor REG4 promotes cancer stem cell properties via Wnt/β‐catenin signaling

Hwang, J., Yoon, J., Cho, Y., Cha, P.-H., Park, J., & Choi, K. (2019) · International Journal of Cancer · doi:10.1002/ijc.32728 · Cited by 44 · see citing works

Regulatory links between PLC enzymes and Ras superfamily GTPases: Signalling via PLCɛ

Bunney, T. D., Baxendale, R. W., & Katan, M. (2009) · Advances in Enzyme Regulation · doi:10.1016/j.advenzreg.2009.01.004 · Cited by 42 · see citing works

Disruption of the Interaction of RAS with PI 3-Kinase Induces Regression of EGFR-Mutant-Driven Lung Cancer

Murillo, M. M., Rana, S., Spencer‐Dene, B., Nye, E. L., Stamp, G., & Downward, J. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.12.003 · Cited by 41 · see citing works

High Mutability of the Tumor Suppressor Genes RASSF1 and RBSP3 (CTDSPL) in Cancer

Kashuba, V. I., Pavlova, T. V., Витальевна, Г. Э., Kutsenko, A. S., Yenamandra, S. P., Li, J., Wang, F., Protopopov, A. I., Zabarovska, V. I., Senchenko, V. N., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005231 · Cited by 40 · see citing works

Impairment of K‐Ras signaling networks and increased efficacy of epidermal growth factor receptor inhibitors by a novel synthetic miR‐143

Akao, Y., Kumazaki, M., Shinohara, H., Sugito, N., Kuranaga, Y., Tsujino, T., Yoshikawa, Y., & Kitade, Y. (2018) · Cancer Science · doi:10.1111/cas.13559 · Cited by 40 · see citing works

RASSF1A Deficiency Enhances RAS-Driven Lung Tumorigenesis

Schmidt, M., Hobbing, K. R., Donninger, H., & Clark, G. J. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-2466 · Cited by 40 · see citing works

Structural snapshots of RAF kinase interactions

Adariani, S. R., Buchholzer, M., Akbarzadeh, M., Nakhaei‐Rad, S., Dvorský, R., & Ahmadian, M. R. (2018) · Biochemical Society Transactions · doi:10.1042/bst20170528 · Cited by 40 · see citing works

Molecular mechanisms of tumor resistance to PI3K-mTOR-targeted therapy

Tan, J. Y., & Yu, Q. (2013) · 癌症：英文版 · doi:10.5732/cjc.012.10287 · Cited by 39 · see citing works

Oncogenic mutations and dysregulated pathways in obesity-associated hepatocellular carcinoma

Shen, J., Tsoi, H., Liang, Q., Chu, E., Liu, D.-B., Yu, C., Chan, T., Li, X., Sung, J. J. Y., Wong, V., et al. (2016) · Oncogene · doi:10.1038/onc.2016.162 · Cited by 39 · see citing works

Oncogenic KRAS provides a uniquely powerful and variable oncogenic contribution among RAS family members in the colonic epithelium

Keller, J. W., Franklin, J. L., Graves‐Deal, R., Friedman, D. B., Whitwell, C. W., & Coffey, R. J. (2006) · Journal of Cellular Physiology · doi:10.1002/jcp.20898 · Cited by 36 · see citing works

Phosphoproteomic Analyses of NRAS(G12) and NRAS(Q61) Mutant Melanocytes Reveal Increased CK2α Kinase Levels in NRAS(Q61) Mutant Cells

Posch, C., Sanlorenzo, M., Vujic, I., Osés-Prieto, J. A., Cholewa, B. D., Kim, S. T., Ma, J. A., Lai, K., Zekhtser, M., Esteve‐Puig, R., et al. (2016) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2016.05.098 · Cited by 35 · see citing works

Targeting group I p21-activated kinases to control malignant peripheral nerve sheath tumor growth and metastasis

Semenova, G., Stepanova, D. S., Dubyk, C. W., et al. (2017) · Oncogene · doi:10.1038/onc.2017.143 · Cited by 35 · see citing works

The Panel of 12 Cell-Free MicroRNAs as Potential Biomarkers in Prostate Neoplasms

Konoshenko, M. Y., Lekchnov, E. A., Bryzgunova, O. E., Zaporozhchenko, I. A., Yarmoschuk, S. V., Pashkovskaya, O. A., Pak, S. V., & Laktionov, P. P. (2020) · Diagnostics · doi:10.3390/diagnostics10010038 · Cited by 35 · see citing works

Effect of PAK Inhibition on Cell Mechanics Depends on Rac1

Mierke, C. T., Puder, S., Aermes, C., Fischer, T., & Kunschmann, T. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00013 · Cited by 35 · see citing works

HRAS mutants identified in Costello syndrome patients can induce cellular senescence: possible implications for the pathogenesis of Costello syndrome

Niihori, T., Aoki, Y., Okamoto, N., Kurosawa, K., Ohashi, H., Mizuno, S., Kawame, H., Inazawa, J., Ohura, T., Arai, H., et al. (2011) · Journal of Human Genetics · doi:10.1038/jhg.2011.85 · Cited by 34 · see citing works

Pivotal Role of the Chromatin Protein Nupr1 in Kras-Induced Senescence and Transformation

Grasso, D., Bintz, J., Lomberk, G. A., Molejon, M. I., Loncle, C., Garcia, M. N., López‐Millán, B., Urrutia, R. A., & Iovanna, J. (2015) · Scientific Reports · doi:10.1038/srep17549 · Cited by 34 · see citing works

The multifunctional role of phospho-calmodulin in pathophysiological processes

Villalobo, A. (2018) · Biochemical Journal · doi:10.1042/bcj20180755 · Cited by 34 · see citing works

The UCA1/KRAS axis promotes human pancreatic ductal adenocarcinoma stem cell properties and tumor growth.

Liu, Y., Feng, W., Gu, S., Wang, H., Zhang, Y., Chen, W., Xu, W., Chen, L., Gong, A., & Xu, M. (2019) · Europe PMC (PubMed Central) · Cited by 34 · see citing works

Pumping the brakes on RAS – negative regulators and death effectors of RAS

Stewart, D. R. H., & Clark, G. J. (2020) · Journal of Cell Science · doi:10.1242/jcs.238865 · Cited by 33 · see citing works

WDR76 degrades RAS and suppresses cancer stem cell activation in colorectal cancer

Ro, E. J., Cho, Y., Jeong, W.-J., Park, J., Min, D. S., & Choi, K. (2019) · Cell Communication and Signaling · doi:10.1186/s12964-019-0403-x · Cited by 31 · see citing works

OncogenicHRASmutations cause prolonged PI3K signaling in response to epidermal growth factor in fibroblasts of patients with Costello syndrome

Rosenberger, G., Meien, S., & Kutsche, K. (2008) · Human Mutation · doi:10.1002/humu.20855 · Cited by 30 · see citing works

Hippo andrassf1aPathways: A Growing Affair

Fausti, F., Agostino, S. D., Sacconi, A., Strano, S., & Blandino, G. (2012) · Molecular Biology International · doi:10.1155/2012/307628 · Cited by 29 · see citing works

Ras effectors: Buying shares in Ras plc

Cullen, P. J. (2001) · Current Biology · doi:10.1016/s0960-9822(01)00189-0 · Cited by 29 · see citing works

Distinct Genetic Alterations in the Mitogen-Activated Protein Kinase Pathway Dictate Sensitivity of Thyroid Cancer Cells to Mitogen-Activated Protein Kinase Kinase 1/2 Inhibition

Schweppe, R. E., Kerege, A. A., Sharma, V., Poczobutt, J. M., Gutierrez‐Hartmann, A., Grzywa, R. L., & Haugen, B. R. (2009) · Thyroid · doi:10.1089/thy.2008.0362 · Cited by 28 · see citing works

KRAS and HRAS mutations confer resistance to MET targeting in preclinical models of MET‐expressing tumor cells

Leiser, D., Medová, M., Mikami, K., Nisa, L., Stroka, D., Blaukat, A., Bladt, F., Aebersold, D. M., & Zimmer, Y. (2015) · Molecular Oncology · doi:10.1016/j.molonc.2015.04.001 · Cited by 28 · see citing works

Ras Regulates Rb via NORE1A

Barnoud, T., Donninger, H., & Clark, G. J. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.697557 · Cited by 26 · see citing works

WNT5A-Induced Activation of the Protein Kinase C Substrate MARCKS Is Required for Melanoma Cell Invasion

Mohapatra, P., Yadav, V. K., Toftdahl, M., et al. (2020) · Cancers · doi:10.3390/cancers12020346 · Cited by 25 · see citing works

Single-molecule fluorescence imaging of RalGDS on cell surfaces during signal transduction from Ras to Ral

Yoshizawa, R., Umeki, N., Yanagawa, M., Murata, M., & Sako, Y. (2017) · Biophysics and Physicobiology · doi:10.2142/biophysico.14.0_75 · Cited by 24 · see citing works

Comparison of growth factor signalling pathway utilisation in cultured normal melanocytes and melanoma cell lines

Kim, J. E., Stones, C. J., Joseph, W. R., Leung, E. Y., Finlay, G. J., Shelling, A. N., Phillips, W. A., Shepherd, P. R., & Baguley, B. C. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-141 · Cited by 22 · see citing works

RASSF Family Proteins and Ras Transformation

Vos, M. D., & Clark, G. J. (2006) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(05)07026-6 · Cited by 17 · see citing works

Non-Redundant and Overlapping Oncogenic Readouts of Non-Canonical and Novel Colorectal Cancer KRAS and NRAS Mutants

Alcantara, K. M. M., Malapit, J. R. P., Yu, R. T. D., Garrido, J. A. M. G., Rigor, J. P. T., Angeles, A. K., la Paz, E. M. C., & Garcia, R. L. (2019) · Cells · doi:10.3390/cells8121557 · Cited by 15 · see citing works

Are all RAS mutations the same? Coexisting KRAS and NRAS mutations in a caecal adenocarcinoma and contiguous tubulovillous adenoma

Vagaja, N., Parry, J., McCallum, D., Thomas, M., & Bentel, J. M. (2015) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2015-202969 · Cited by 14 · see citing works

Altered miR-21, miRNA-148a Expression in Relation to KRAS Mutation Status as Indicator of Adenoma-Carcinoma Transitional Pattern in Colorectal Adenoma and Carcinoma Lesions

Igder, S., Asl, J. M., & Mokarram, P. (2019) · Biochemical Genetics · doi:10.1007/s10528-019-09918-0 · Cited by 14 · see citing works

MicroRNA Expression and Correlation with mRNA Levels of Colorectal Cancer-Related Genes

Moghadamnia, F., Ghoraeian, P., Minaeian, S., Talebi, A., Farsi, F., & Akbari, A. (2019) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-019-00249-2 · Cited by 12 · see citing works

Wild‐type K‐ras has a tumour suppressor effect on carcinogen‐induced murine colorectal adenoma formation

Luo, F., Poulogiannis, G., Ye, H., Hamoudi, R., Dong, G., Zhang, W., Ibrahim, A. E. K., & Arends, M. J. (2013) · International Journal of Experimental Pathology · doi:10.1111/iep.12064 · Cited by 10 · see citing works

Mutant NRAS Q61K is responsible for MAPK pathway activation in the MARIMO cell line and renders these cells independent of the CALR–MPL–JAK2–STAT5 pathway

Han, L., Czech, J., Maurer, A., Brümmendorf, T. H., Chatain, N., & Koschmieder, S. (2018) · Leukemia · doi:10.1038/s41375-018-0234-6 · Cited by 10 · see citing works

Protein kinase C modulates negatively the hepatocyte growth factor-induced migration, integrin expression and phosphatidylinositol 3-kinase activation

Gujdár, A., Sipeki, S., Bander, E., et al. (2003) · Cellular Signalling · doi:10.1016/j.cellsig.2003.09.009 · Cited by 8 · see citing works

Detection of N-RAS and K-RAS in their active GTP-bound form in acute myeloid leukemia without activatingRASmutations

Ehmann, F., Horn, S., Garcia-Palma, L., et al. (2006) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190600565925 · Cited by 8 · see citing works

Downregulation of miR‑143 modulates KRAS expression in colorectal carcinoma cells

Liu, H., Liu, J., Huo, J., Li, K., Li, K., Guo, H., & Yang, Y. (2019) · Oncology Reports · doi:10.3892/or.2019.7359 · Cited by 8 · see citing works

Suppression of PKC causes oncogenic stress for triggering apoptosis in cancer cells

Ganapathy, S., Peng, B., Shen, L., Yu, T., Lafontant, J., Li, P., Xiong, R., Makriyannis, A., & Chen, C. (2017) · Oncotarget · doi:10.18632/oncotarget.16047 · Cited by 7 · see citing works

Constitutive Expression of NRAS with Q61R Driver Mutation Activates Processes of Epithelial–Mesenchymal Transition and Leads to Substantial Transcriptome Change of Nthy-ori 3–1 Thyroid Epithelial Cells

Демин, Д. Э., Afanasyeva, M. A., Uvarova, A. N., Prokofjeva, M. M., Gorbachova, A. M., Ustiugova, A. S., Klepikova, A. V., Putlyaeva, L. V., Tatosyan, K. A., Belousov, P. V., et al. (2019) · Biochemistry (Moscow) · doi:10.1134/s0006297919040096 · Cited by 7 · see citing works

Constitutively active Ras negatively regulates Erk MAP kinase through induction of MAP kinase phosphatase 3 (MKP3) in NIH3T3 cells

Park, Y. J., Lee, J. M., Shin, S. Y., & Kim, Y. H. (2014) · BMB Reports · doi:10.5483/bmbrep.2014.47.12.017 · Cited by 6 · see citing works

Ligand-mimetic anti-aIIbβ3 antibody PAC-1 inhibits tyrosine signaling, proliferation and lung colonization of melanoma cells

Rásó, E., Tóvári, J., Ladányi, A., et al. (2005) · Pathology & Oncology Research · doi:10.1007/bf02893854 · Cited by 6 · see citing works

Drugging KRAS: Current perspectives and state-of-art review

Parikh, K., Banna, G., Liu, S. V., Friedlaender, A., Desai, A., Subbiah, V., & Addeo, A. (2022) · Journal of Hematology &amp; Oncology · doi:10.1186/s13045-022-01375-4 · Cited by 164 · see citing works

Glecirasib, a Potent and Selective Covalent KRAS G12C Inhibitor Exhibiting Synergism with Cetuximab or SHP2 Inhibitor JAB-3312

Wang, P., Sun, X., He, X., Kang, D., Liu, X., Liu, D., Li, A., Yang, G., Lin, Y., Li, S., et al. (2025) · Cancer Research Communications · doi:10.1158/2767-9764.crc-25-0001 · Cited by 9 · see citing works

Solanine Interferes with AKT/p-AKT and PI3K/p-PI3K Pathway to Inhibit HIF and Destroy Cell Energy Metabolism

Wang, Y., Wang, P., & Zhao, W. (2021) · Journal of Biosciences and Medicines · doi:10.4236/jbm.2021.910008 · Cited by 1 · see citing works

Reactivation of AKT signaling following treatment of cancer cells with PI3K inhibitors attenuates their antitumor effects

Dufour, M., Dormond-Meuwly, A., Pythoud, C., Demartines, N., & Dormond, O. (2013) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2013.07.014 · Cited by 21 · see citing works

FoxO Transcription Factors Promote AKT Ser473 Phosphorylation and Renal Tumor Growth in Response to Pharmacologic Inhibition of the PI3K–AKT Pathway

Lin, A., Piao, H.-L., Li, Z., Sarbassov, D. D., Ma, L., & Gan, B. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-1729 · Cited by 148 · see citing works

Virtual Docking Screening and QSAR Studies to Explore PI3K and mTOR Inhibitors Acting on AKT in Cancers

Kandoussi, I., Benherrif, O., Lakhlili, W., et al. (2020) · Journal of Cancer Science and Clinical Therapeutics · doi:10.26502/jcsct.5079099 · Cited by 1 · see citing works

Solanine Interferes With AKT/p-AKT and PI3K/ p-PI3K to Inhibit HIF and Destroy Cell Energy MetabolismPreprint

Wang, P., & Wang, Y. (2021) · Research Square · doi:10.21203/rs.3.rs-663150/v1